CHMP green light for Bayer/Algeta's Xofigo
This article was originally published in Scrip
Executive Summary
In its latest round of opinions, Bayer secured a positive recommendation from the EU's Committee for Medicinal Products for Human Use (CHMP) for Xofigo (radium-223 dichloride) for approval as a treatment for adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It was approved by the US FDA in May (scripintelligence.com, 16 May 2013).